• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

One-Year Risk of Stroke After Transient Ischemic Attack or Minor Stroke in Hunter New England, Australia (INSIST Study)
Conclusion: One-year risk of stroke in TIAMS participants was lower than reported in previous studies. Early implementation of antiplatelet/anticoagulant therapies may have contributed to the low stroke recurrence.
Source: Frontiers in Neurology - December 20, 2021 Category: Neurology Source Type: research

Use of health and aged care services in Australia following hospital admission for myocardial infarction, stroke or heart failure
Cardiovascular diseases (CVD), including myocardial infarction (MI), stroke and heart failure (HF) are the leading cause of death amongst the older population worldwide. The aim of this study is to investigate...
Source: BMC Geriatrics - October 11, 2021 Category: Geriatrics Authors: Benjumin Hsu, Rosemary J. Korda, Richard I. Lindley, Kirsty A. Douglas, Vasi Naganathan and Louisa R. Jorm Tags: Research Source Type: research

Factors that influence whether patients with acute coronary syndromes undergo cardiac catheterisation
CONCLUSIONS: Although a larger proportion of patients who presented to catheterisation-capable hospitals underwent catheterisation, patients with similar characteristics were selected for the procedure, independent of the hospital of presentation. Major outcomes for patients were also similar, suggesting equitable management of patients with ACS across Australia.PMID:33792058 | DOI:10.5694/mja2.50997
Source: Med J Aust - April 1, 2021 Category: General Medicine Authors: Michael Ayad Karice Hyun Mario D'Souza Julie Redfern Janice Gullick Mark Ryan David B Brieger Source Type: research

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Estimating the public economic consequences of cardiovascular disease-attributable events and evolocumab treatment in Australia.
CONCLUSIONS: Applying a cross-sectorial government perspective budget impact assessment improves our understanding of fiscal changes attributed to ASCVD based on changes in premature mortality and work activity and how this influences lifetime tax contributions and public benefits. The main cost driver observed was associated with reduced ASCVD events that enabled people to remain productive and paying taxes. PMID: 33464137 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - January 20, 2021 Category: Health Management Tags: J Med Econ Source Type: research

Clinical features, sex differences and outcomes of myocardial infarction with nonobstructive coronary arteries: a registry analysis
Conclusion The incidence of MINOCA was 9.5%. Compared to OACD-MI, patients with MINOCA have less cardiac risk factors. In-hospital outcomes of patients diagnosed with MINOCA were better than OACD-MI.
Source: Coronary Artery Disease - December 23, 2020 Category: Cardiology Tags: Acute Coronary Syndromes Source Type: research

Intermountain chronic disease risk score (ICHRON) validation for prediction of incident chronic disease diagnoses in an australian primary prevention population.
CONCLUSION: ICHRON predicted ChrD diagnosis at 3-years among an external, geographically distant validation cohort. These findings show the value of ICHRON for primary care patients in distinct locales. Additionally, electronic calculation of ICHRON empowers the clinical use of this tool to identify and differentially manage and treat high-risk patients. PMID: 32563688 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - June 16, 2020 Category: Internal Medicine Authors: May HT, Anderson JL, Muhlestein JB, Knowlton KU, Horne BD Tags: Eur J Intern Med Source Type: research

Cardiac Rehabilitation and Secondary Prevention Roundtable: Australian Implementation and Research Priorities
Cardiovascular disease (CVD), including coronary heart disease (CHD) and stroke, is the leading cause of death and disease burden globally [1]. CVD resulted in>1.1 million hospitalisations in 2015-16, and incurs the highest level of health care sector expenditure in Australia (11-12% of total health expenditure) [2]. CHD accounts for the greatest single disease morbidity (>500,000 bed-days annually) and nearly one fifth of all deaths with a total cost of $1.14 billion annually [2]. Over 65,000 Australians experience an acute coronary event (heart attack or unstable angina) each year [3], and, importantly, around a third of...
Source: Heart, Lung and Circulation - February 28, 2020 Category: Cardiology Authors: Julie Redfern, Gemma Figtree, Clara Chow, Garry Jennings, Tom Briffa, Robyn Gallagher, Rachelle Foreman, on behalf of Roundtable Attendees Tags: Editorial Source Type: research

Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial
This study is registered with Clinicaltrials.gov, NCT01335087 and is now closed.FindingsBetween April 25, 2011, and Feb 2, 2018, a total of 2834 patients with ACS had respiratory polygraphy, of whom 2551 (90·01%) were recruited. 1264 (49·55%) patients had OSA and were randomly assigned to the CPAP group (n=633) or the UC group (n=631). 1287 (50·45%) patients did not have OSA, of whom 603 (46·85%) were randomly assigned to the reference group. Patients were followed up for a median of 3·35 years (IQR 1·50–5·31). The prevalence of cardiovascular events was similar in the CPAP and UC groups (98 events [16%] vs 108 ev...
Source: The Lancet Respiratory Medicine - December 14, 2019 Category: Respiratory Medicine Source Type: research

Staying muscly 'could ward off heart disease in middle-aged men'
Researchers in Australia followed more than 500 men over 45 for ten years. The muscleiest were up to 81 per cent less likely to have a heart attack or stroke than the least muscleiest.
Source: the Mail online | Health - November 11, 2019 Category: Consumer Health News Source Type: news

Pages: 1  2  3  4  5  6  7